Join
Live feed
·
PRReleasevia Quantisnow
Upstream Bio Inc. logo

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

ByQuantisnow·Wall Street's wire, on your screen.
UPB· Upstream Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track UPB (Upstream Bio Inc.) and more on Quantisnow.